Intas Pharma signs licensing pact with mAbxience for etanercept biosimilar EP News Bureau Dec 26, 2023 Intas gains exclusive commercialisation rights for Etanercept biosimilar for more than 150 countries worldwide
US FDA accepts Amneal’s Biologics License Application for Bevacizumab EP News Bureau Jun 17, 2021 Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA
Argentina and Mexico to make AstraZeneca COVID-19 vaccine for Latin America Reuters Aug 13, 2020 The deal between AstraZeneca and mAbxience of the INSUD Group includes technology to initially produce 150 million doses of the…
